New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:58 EDTADXSAdvaxis evaluated higher dose, repeat cycles of ADXS-HPV in Phase 1/2 trial
Advaxis announced that the Georgia Regents University, or GRU, Cancer Center has received Institutional Review Board, or IRB, approval to initiate a Phase 1/2 trial evaluating higher doses and repeat cycles of ADXS-HPV in patients with recurrent cervical cancer. The trial will be conducted at GRU under the direction of Dr. Samir Khleif, Director, GRU Cancer Center. ADXS-HPV is Advaxis's lead Lm-LLO cancer immunotherapy product candidate, designed to target HPV-associated cancers. This Phase 1/2 study is designed to evaluate the safety, efficacy and immunological effect of the highest-tolerated dose of ADXS-HPV administered in repeat cycles of treatment to patients with cervical cancer whose disease recurred after receiving one prior cytotoxic treatment regimen. Advaxis's earlier Phase 2 clinical study in 110 women with recurrent cervical cancer had already demonstrated that a single cycle of ADXS-HPV at a dose of 1x109 colony forming units, or CFU, is well-tolerated with complete and partial tumor responses as well as an apparent survival benefit. Building on this data, among the purposes of this study is to evaluate the effect of repeat cycles of treatment of ADXS-HPV at higher doses.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
07:35 EDTADXSAdvaxis, Sorrento Therapeutics form collaboration
Subscribe for More Information
May 15, 2015
10:01 EDTADXSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:11 EDTADXSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Bsquare (BSQR), up 34.2%... Applied Materials (AMAT), up 3.2%. ALSO HIGHER: Trillium Therapeutics (TRIL), up 13% after being initiated with an Outperform at Oppenheimer... Pernix Therapeutics (PTX), up 7.4% after announcing FDA approval of Treximet for use in pediatric patients... Advaxis (ADXS), up 4.4% after being initiated with a Buy at Jefferies... Netflix (NFLX), up 3.3% following a Bloomberg report that the company is in talks to enter China's online video market... Inovalon (INOV), up 2.9% after being upgraded to Buy from Neutral at Goldman. DOWN AFTER EARNINGS: El Pollo LoCo (LOCO), down 12.8%... King Digital (KING), down 8.3%. ALSO LOWER: PlasmaTech (PTBI), down 5.4% after filing to sell 1.93M shares for selling stockholders... Paycom Software (PAYC), down 7% after 8M share Spot Secondary priced at $36.25... Keurig Green Mountain (GMCR), down 5.9% after Keurig Kold investor presentation... 3D Systems (DDD), down 2.4% after CFO transition... Celladon (CLDN), down 5.1% after the CEO says that the company is evaluating strategic options.
07:33 EDTADXSAdvaxis initiated with a Buy at Jefferies
Target $27.
May 14, 2015
16:53 EDTADXSAdvaxis initiated with a Buy at Janney Capital
Subscribe for More Information
10:00 EDTADXSOn The Fly: Analyst Initiation SummaryT
Today's noteworthy initiations include: Advaxis (ADXS) initiated with a Buy at MLV & Co.... Akebia (AKBA) initiated with a Buy at Brean Capital... CarMax (KMX) initiated with a Buy at Sterne Agee CRT... Coach (COH) initiated with a Neutral at Wedbush... Euronav NV (EURN) initiated with an Outperform at Credit Suisse... Franco-Nevada (FNV) initiated with an Outperform at Macquarie... Kate Spade (KATE) initiated with an Outperform at Wedbush... Lumber Liquidators (LL) initiated with a Perform at Oppenheimer... Michael Kors (KORS) initiated with a Neutral at Wedbush... National Instruments (NATI) initiated with an Overweight at Stephens... Royal Gold (RGLD) initiated with an Outperform at Macquarie... Spectra Energy Partners (SEP) initiated with a Buy at Janney ... Spectra Energy (SE) initiated with a Buy at Janney Capital... Tribune Publishing (TPUB) initiated with a Buy at Sterne Agee CRT.
07:48 EDTADXSAdvaxis initiated with a Buy at MLV & Co.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use